ClinicalTrials.gg
RecruitingNCT03678025Updated Oct 8, 2026

Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

A Phase 3 interventional study of Abiraterone and Bicalutamide in Castration Levels of Testosterone, Metastatic Prostatic Adenocarcinoma and Stage IV Prostate Cancer AJCC v8, sponsored by SWOG Cancer Research Network. Recruiting at 338 sites in 5 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by SWOG Cancer Research Network · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2018; still recruiting 8 years 1 month later.
Updated Oct 8, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,273
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Prostatic Neoplasms by SWOG Cancer Research Network — 3 open to participants now, 3 under way, 2 of them phase 3. Prostatic Neoplasms · SWOG Cancer Research Network.

Planned enrollment
4th of 15
1,273 · median 619
Started
2018
the only one that year
Phase 3
9 of 19
2 open now
Registered
17th of 19
by date

Among the 19 studies in Prostatic Neoplasms by SWOG Cancer Research Network, this one is the 4th largest by planned enrollment of the 15 interventional ones that give a count, is the only one that started in 2018, is one of 9 in phase 3, and was the 17th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

3 of the 19 studies in Prostatic Neoplasms by SWOG Cancer Research Network are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Prostatic Neoplasms by SWOG Cancer Research Network, or all of them as a file.
02

Study summary

This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the body. Addition of prostate removal surgery or radiation therapy to standard systemic therapy for prostate cancer may lower the chance of the cancer growing or spreading.

Read the detailed description

PRIMARY OBJECTIVES:

I. To compare overall survival in metastatic prostate cancer patients who are randomized to standard systemic therapy (SST) plus definitive treatment of the primary tumor versus standard systemic therapy alone.

SECONDARY OBJECTIVES:

I. To compare overall survival in metastatic prostate cancer patients who received SST plus surgical excision of the primary tumor versus SST alone in the subset who specify the surgical intent stratification factor.

II. To compare the rate of symptomatic local progression between the treatment arms.

III. To compare progression-free survival (PFS) between the two treatment arms. IV. To compare rates of progression-free survival between arms for the subsets of patients with and without metastasis directed therapy (MDT) to oligometastatic sites.

QUALITY OF LIFE OBJECTIVES:

I. To compare between arms patient-reported urinary function and urinary bother over time (after initiation of SST at 6 months, 1, 2, and 3 years) using the Expanded Prostate Cancer Index Composite (EPIC) and patient-reported pain and physical functioning using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) between patients receiving standard systemic therapy and those receiving systemic therapy and definitive management of the primary prostate cancer.

OTHER OBJECTIVES:

I. To bank tissue and whole blood specimens for future use.

OUTLINE:

INDUCTION: Participants receive 1 of 6 acceptable forms of SST for 22-28 weeks. I. Participants undergo a bilateral orchiectomy. II. Participants receive goserelin acetate subcutaneously (SC) every 28 days or 12 weeks, histrelin acetate SC every 12 months, leuprolide acetate SC or intramuscularly (IM) every 1, 3, 4, or 6 months, and triptorelin every 1, 3, or 6 months.

III. Participants receive goserelin acetate SC every 28 days or 12 weeks, histrelin acetate SC every 12 months, leuprolide acetate SC or IM every 1, 3, 4, or 6 months, and triptorelin every 1, 3, or 6 months. Participants also receive nilutamide orally (PO) daily, flutamide PO every 8 hours, and bicalutamide PO daily.

IV. Participants receive degarelix via injection for 2 doses and then every 28 days.

V. Participants receive nilutamide PO daily, flutamide PO every 8 hours, and bicalutamide PO daily. Participants also receive docetaxel over 1 hour every 3 weeks with or without prednisone PO every 12 hours.

VI. Participants receive nilutamide PO daily, flutamide PO every 8 hours, and bicalutamide PO daily. Participants also receive abiraterone PO daily or prednisone PO every 12 hours.

After completion of 22-28 weeks of SST, participants are then randomized to 1 of 2 arms.

ARM I: Participants receive 1 acceptable form of SST as in Induction except for treatment with docetaxel and prednisone.

ARM II: Participants receive 1 acceptable form of SST as in Induction except for treatment with docetaxel and prednisone. Participants undergo prostatectomy within 8 weeks after randomization or radiation therapy within 4 weeks of randomization.

After completion of study treatment, participants are followed up for 8 years.

03

Conditions studied

  • Castration Levels of Testosterone
  • Metastatic Prostatic Adenocarcinoma
  • Stage IV Prostate Cancer AJCC v8
  • Stage IVA Prostate Cancer AJCC v8
  • Stage IVB Prostate Cancer AJCC v8

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • STEP 1 REGISTRATION: DISEASE-RELATED CRITERIA: All patients must have a or cytologically proven diagnosis of adenocarcinoma of the prostate. Patients with pure small cell carcinoma* (SCC), sarcomatoid, or squamous cell carcinoma are not eligible. (*morphology must be consistent with SCC; synaptophysin or chromogranin positive by immunohistochemical staining is insufficient to diagnose SCC).
  • STEP 1 REGISTRATION: DISEASE-RELATED CRITERIA: Patients must have an intact prostate. No prior local therapy for prostate adenocarcinoma is allowed (e.g., brachytherapy, high-intensity focused ultrasound [HIFU], cryotherapy, laser ablative therapies). Any prior therapy for benign conditions, such as obstruction, are acceptable (e.g., transurethral resection of the prostate, greenlight laser ablation, microwave ablation).
  • STEP 1 REGISTRATION: DISEASE-RELATED CRITERIA: Patients must have evidence of disease on technetium bone scan and computed tomography (CT) or magnetic resonance imaging (MRI) within 42 days prior to starting standard systemic therapy. Metastatic disease that is detected by positron emission tomography (PET) scan only (sodium fluoride [NaF], prostate-specific membrane antigen [PSMA], anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid [FACBC], carbon [C]11) but not conventional imaging (technetium [Tc]99 bone scan, CT or MRI) or solitary metastases by conventional imaging, must be confirmed histologically or cytologically.
  • STEP 1 REGISTRATION: DISEASE-RELATED CRITERIA: Patients with known are not eligible. Brain imaging studies are not required for eligibility if the patient has no neurologic signs or symptoms suggestive of brain metastasis. If brain imaging studies are performed, they must be negative for disease.
  • STEP 1 REGISTRATION: PRIOR/CONCURRENT THERAPY CRITERIA: Patients must have received no more than 28 weeks of standard systemic therapy (SST). SST is defined as current National Comprehensive Cancer Network (NCCN) guidelines for metastatic prostate cancer.
  • STEP 1 REGISTRATION: PRIOR/CONCURRENT THERAPY CRITERIA: Patients must not have progressed while on SST.
  • STEP 1 REGISTRATION: PRIOR/CONCURRENT THERAPY CRITERIA: Patients with oligometastatic prostate cancer may receive metastasis directed therapy to up to four sites of disease prior to randomization.
  • STEP 1 REGISTRATION: CLINICAL/LABORATORY CRITERIA: Patients must have a complete physical examination and medical history within 28 days prior to registration.
  • STEP 1 REGISTRATION: CLINICAL/LABORATORY CRITERIA: Patients must have a PSA documented prior to initiation of SST and within 28 days prior to registration. Any additional PSAs measured while receiving SST should be recorded.
  • STEP 1 REGISTRATION: CLINICAL/LABORATORY CRITERIA: Patients must have a testosterone lab documented within 28 days prior to randomization. Any additional testosterone labs measured while receiving SST should be recorded as well as pretreatment initiation if available.
  • STEP 1 REGISTRATION: CLINICAL/LABORATORY CRITERIA: No other prior is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, adequately treated stage 0, I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease free for three years.
  • STEP 1 REGISTRATION: SPECIMEN SUBMISSION CRITERIA: Patients must be offered the opportunity to participate in translational medicine studies and specimen banking for future studies.
  • STEP 1 REGISTRATION: QUALITY OF LIFE CRITERIA: Patients who can complete Patient-Reported Outcome instruments in English, Spanish or French, must participate in the quality of life studies.
  • STEP 1 REGISTRATION: REGULATORY CRITERIA: Patients must be informed of the nature of this study and must sign and give written in accordance with institutional and federal guidelines.
  • STEP 2 RANDOMIZATION: DISEASE-RELATED CRITERIA: As a part of the OPEN registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system.
  • STEP 2 RANDOMIZATION: DISEASE-RELATED CRITERIA: Patients must have no evidence of disease progression during the 28 weeks of SST by PSA measure, bone scan and CT or MRI or symptomatic deterioration (as defined by physician discretion) within 28 days prior to randomization.
  • STEP 2 RANDOMIZATION: DISEASE-RELATED CRITERIA: Patients must have consultation with a urologist and have surgically resectable disease regardless of definitive treatment intent or randomization.
  • STEP 2 RANDOMIZATION: PRIOR/CONCURRENT THERAPY CRITERIA: Patients must have received between 22 and 28 weeks of SST as measured from the date of first hormonal therapy or surgical castration. SST is defined by current NCCN guidelines for metastatic prostate cancer.
  • STEP 2 RANDOMIZATION: PRIOR/CONCURRENT THERAPY CRITERIA: Patients must not be planning to receive docetaxel after randomization.
  • STEP 2 RANDOMIZATION: PRIOR/CONCURRENT THERAPY CRITERIA: Any toxicities from SST must have resolved to =\< grade 1 ( [CTCAE] version 5.0) prior to randomization.
  • STEP 2 RANDOMIZATION: PRIOR/CONCURRENT THERAPY CRITERIA: Patients may have received elective metastasis directed therapy to oligometastatic sites (=\< 4 sites). All treatment must be completed prior to randomization.
  • STEP 2 RANDOMIZATION: CLINICAL/LABORATORY CRITERIA: Patients must have a PSA performed within 28 days prior to randomization.
  • STEP 2 RANDOMIZATION: CLINICAL/LABORATORY CRITERIA: Patients must have a testosterone \< 50 ng/dL within 28 days prior to randomization.
  • STEP 2 RANDOMIZATION: CLINICAL/LABORATORY CRITERIA: Patients must have a Zubrod performance status of 0 ? 1 within 28 days prior to randomization.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,273 participants (estimated)

Study arms

  • Active comparator
    Arm I (SST)

    Participants receive 1 acceptable form of SST as in Induction except for treatment with docetaxel and prednisone.

    Drug: Abiraterone · Drug: Bicalutamide · Drug: Degarelix · Drug: Flutamide · Drug: Goserelin Acetate · Drug: Histrelin Acetate · Drug: Leuprolide Acetate · Drug: Nilutamide · Procedure: Orchiectomy · Other: Quality-of-Life Assessment · Drug: Triptorelin

  • Experimental
    Arm II (SST, prostatectomy or radiation therapy)

    Participants receive 1 acceptable form of SST as in Induction except for treatment with docetaxel and prednisone. Participants undergo prostatectomy within 8 weeks after randomization or radiation therapy within 4 weeks of randomization.

    Drug: Abiraterone · Drug: Bicalutamide · Drug: Degarelix · Drug: Flutamide · Drug: Goserelin Acetate · Drug: Histrelin Acetate · Drug: Leuprolide Acetate · Drug: Nilutamide · Procedure: Orchiectomy · Other: Quality-of-Life Assessment · Radiation: Radiation Therapy · Procedure: Radical Prostatectomy · Drug: Triptorelin

  • Active comparator
    Step 1 (pre-randomization)

    Standard treatment data collection prior to randomization

    Drug: Abiraterone · Drug: Bicalutamide · Drug: Degarelix · Drug: Docetaxel · Drug: Flutamide · Drug: Goserelin Acetate · Drug: Histrelin Acetate · Drug: Leuprolide Acetate · Drug: Nilutamide · Procedure: Orchiectomy · Drug: Prednisone · Other: Quality-of-Life Assessment · Drug: Triptorelin

Interventions

  • Given PO

    Also known as: CB 7598

  • Given PO

    Also known as: Casodex, Cosudex, ICI 176,334, ICI 176334

  • Given via injection

    Also known as: FE200486, Firmagon

  • intravenous

    Also known as: Docecad, RP56976, Taxotere, Taxotere Injection Concentrate

  • Given PO

    Also known as: 4'-Nitro-3'-trifluoromethylisobutyranilide, Apimid, Cebatrol, Chimax, Cytomid, Drogenil, Euflex, Eulexine, Flucinom, Flucinome, Flugerel, Fluken, Flulem, FLUT, Fluta-Gry, Flutabene, Flutacan, Flutamex, Flutamin, Flutan, Flutaplex, Fugerel, Grisetin, Niftolide, Oncosal, Profamid, Propanamide, 2-Methyl-N-(4-nitro-3-(trifluoromethyl)phenyl)-, Prostacur, Prostadirex, Prostica, Prostogenat, SCH 13521, Tafenil, Tecnoflut, Testotard

  • DrugGoserelinStudies of GoserelinGoserelin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Given SC

    Also known as: ZDX, Zoladex

  • DrugHistrelinStudies of HistrelinHistrelin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Receive SC

    Also known as: Supprelin, Vantas

  • DrugLeuprolideStudies of LeuprolideLeuprolide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Receive SC or IM

    Also known as: A-43818, Abbott 43818, Abbott-43818, Carcinil, Depo-Eligard, Eligard, Enanton, Enantone, Enantone-Gyn, Ginecrin, LEUP, Leuplin, Leuprorelin Acetate, Lucrin, Lucrin Depot, Lupron, Lupron Depot, Lupron Depot-3 Month, Lupron Depot-4 Month, Lupron Depot-Ped, Procren, Procrin, Prostap, TAP-144, Trenantone, Uno-Enantone, Viadur

  • Given PO

    Also known as: Anandron, Nilandron, RU-23908

  • ProcedureOrchiectomy

    Undergo bilateral orchiectomy

    Also known as: Castration, Male Castration, Male Gonadectomy, orchidectomy

  • Given PO

    Also known as: .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisonum, Prednitone, Promifen, Servisone, SK-Prednisone

  • OtherQuality-of-Life Assessment

    Ancillary studies

    Also known as: Quality of Life Assessment

  • RadiationRadiation Therapy

    Standard radiation

    Also known as: Cancer Radiotherapy, Irradiate, Irradiated, irradiation, Radiation, Radiotherapeutics, RADIOTHERAPY, RT, Therapy, Radiation

  • ProcedureRadical Prostatectomy

    Standard surgery

    Also known as: Prostatovesiculectomy

  • injection

    Also known as: 6-D-Tryptophan-LH-RH, 6-D-Tryptophanluteinizing Hormone-releasing Factor, AY-25650, CL-118,532, Decapeptyl, Detryptoreline

06

What researchers measure

Primary outcomes

  1. Overall survival (OS)

    Time frame: From date of randomization to date of death due to any cause, assessed up to 8 years

Secondary outcomes

  1. Media OS

    Will compare OS in metastatic prostate cancer patients who received standard systemic therapy (SST) plus surgical excision of the primary tumor versus SST alone in the subset who specify the surgical intent stratification factor.

    Time frame: From date of randomization to date of death due to any cause, assessed up to 8 years

  2. Rate of symptomatic local progression

    Defined as any of the following events post-randomization: Common Terminology Criteria for Adverse Events version 5 grade \>= 2 hematuria, urinary retention, urinary tract obstruction, urinary tract pain, pelvic pain, renal and urinary disorders-other. Will be compared between the treatment arms. A proportional hazards model will be fit to each of these endpoints where the time interval starts at date of randomization to (i) time of first symptomatic local progression or ii) progression or death due to any cause, where those without the event are censored at their last contact date. Stratification factors will be adjusted for as covariates.

    Time frame: Up to 8 years

  3. Progression-free survival (PFS)

    Will be compared between for the subsets of patients with and without metastasis directed therapy (MDT) to oligometastatic sites. A proportional hazards model will be fit to each of these endpoints where the time interval starts at date of randomization to (i) time of first symptomatic local progression or ii) progression or death due to any cause, where those without the event are censored at their last contact date. Stratification factors will be adjusted for as covariates.

    Time frame: From date of randomization to date of first documentation of progression, or death due to any cause, assessed up to 8 years

07

Study locations

297 of 338 sites recruiting
  • Banner MD Anderson Cancer Center
    Gilbert, Arizona 85234, United States
    Recruiting
    • Site Public Contact · Contact602-747-9738
    • Chinedu Mmeje · Principal investigator
  • Cancer Center at Saint Joseph's
    Phoenix, Arizona 85004, United States
    Recruiting
  • Mayo Clinic Hospital in Arizona
    Phoenix, Arizona 85054, United States
    Suspended

    Not enrolling at this site — choose another above.

  • Mayo Clinic in Arizona
    Scottsdale, Arizona 85259, United States
    Suspended

    Not enrolling at this site — choose another above.

  • University of Arizona Cancer Center-Orange Grove Campus
    Tucson, Arizona 85704, United States
    Recruiting
    • Site Public Contact · Contact520-694-8900
    • Juan Chipollini · Principal investigator
  • University of Arizona Cancer Center-North Campus
    Tucson, Arizona 85719, United States
    Recruiting
  • University of Arkansas for Medical Sciences
    Little Rock, Arkansas 72205, United States
    Recruiting
    • Site Public Contact · Contact501-686-8274
    • Shi-Ming Tu · Principal investigator
  • Kaiser Permanente-Deer Valley Medical Center
    Antioch, California 94531, United States
    Recruiting
    • Site Public Contact · ContactKpoct@kp.org · 877-642-4691
    • Andrea L. Harzstark · Principal investigator
  • Community Cancer Institute
    Clovis, California 93611, United States
    Recruiting
    • Site Public Contact · Contact559-387-1827
    • Uzair B. Chaudhary · Principal investigator
  • University Oncology Associates
    Clovis, California 93611, United States
    Suspended

    Not enrolling at this site — choose another above.

  • City of Hope Comprehensive Cancer Center
    Duarte, California 91010, United States
    Recruiting
  • Kaiser Permanente Dublin
    Dublin, California 94568, United States
    Recruiting
    • Site Public Contact · Contact877-642-4691
    • Andrea L. Harzstark · Principal investigator
  • Kaiser Permanente-Fremont
    Fremont, California 94538, United States
    Recruiting
    • Site Public Contact · ContactKpoct@kp.org · 877-642-4691
    • Andrea L. Harzstark · Principal investigator
  • Fresno Cancer Center
    Fresno, California 93720, United States
    Recruiting
    • Site Public Contact · ContactKpoct@kp.org · 877-642-4691
    • Andrea L. Harzstark · Principal investigator
  • Kaiser Permanente-Fresno
    Fresno, California 93720, United States
    Recruiting
    • Site Public Contact · ContactKpoct@kp.org · 877-642-4691
    • Andrea L. Harzstark · Principal investigator
  • UC San Diego Moores Cancer Center
    La Jolla, California 92093, United States
    Recruiting
    • Site Public Contact · Contactcancercto@ucsd.edu · 858-822-5354
    • Aditya Bagrodia · Principal investigator
  • Tibor Rubin VA Medical Center
    Long Beach, California 90822, United States
    Recruiting
    • Site Public Contact · Contact562-826-8000
    • Greg Gin · Principal investigator
  • Los Angeles County-USC Medical Center
    Los Angeles, California 90033, United States
    Recruiting
    • Site Public Contact · Contact323-865-0451
    • Siamak Daneshmand · Principal investigator
  • USC / Norris Comprehensive Cancer Center
    Los Angeles, California 90033, United States
    Recruiting
    • Site Public Contact · Contact323-865-0451
    • Siamak Daneshmand · Principal investigator
  • Fremont - Rideout Cancer Center
    Marysville, California 95901, United States
    Recruiting
    • Site Public Contact · Contact530-749-4400
    • Richard K. Valicenti · Principal investigator
  • Kaiser Permanente-Modesto
    Modesto, California 95356, United States
    Recruiting
    • Site Public Contact · ContactKpoct@kp.org · 877-642-4691
    • Andrea L. Harzstark · Principal investigator
  • Kaiser Permanente Oakland-Broadway
    Oakland, California 94611, United States
    Recruiting
    • Site Public Contact · ContactKpoct@kp.org · 877-642-4691
    • Andrea L. Harzstark · Principal investigator
  • Kaiser Permanente-Oakland
    Oakland, California 94611, United States
    Recruiting
    • Site Public Contact · ContactKpoct@kp.org · 877-642-4691
    • Andrea L. Harzstark · Principal investigator
  • Desert Regional Medical Center
    Palm Springs, California 92262, United States
    Recruiting
    • Site Public Contact · Contact760-416-4730
    • Amir Lavaf · Principal investigator
  • Stanford Cancer Institute Palo Alto
    Palo Alto, California 94304, United States
    Recruiting
  • Kaiser Permanente-Rancho Cordova Cancer Center
    Rancho Cordova, California 95670, United States
    Recruiting
    • Site Public Contact · ContactKpoct@kp.org · 877-642-4691
    • Andrea L. Harzstark · Principal investigator
  • Kaiser Permanente-Redwood City
    Redwood City, California 94063, United States
    Recruiting
    • Site Public Contact · ContactKpoct@kp.org · 877-642-4691
    • Andrea L. Harzstark · Principal investigator
  • Kaiser Permanente-Richmond
    Richmond, California 94801, United States
    Recruiting
    • Site Public Contact · ContactKpoct@kp.org · 877-642-4691
    • Andrea L. Harzstark · Principal investigator
  • Rohnert Park Cancer Center
    Rohnert Park, California 94928, United States
    Recruiting
    • Site Public Contact · ContactKpoct@kp.org · 877-642-4691
    • Andrea L. Harzstark · Principal investigator
  • Kaiser Permanente-Roseville
    Roseville, California 95661, United States
    Recruiting
    • Site Public Contact · ContactKpoct@kp.org · 877-642-4691
    • Andrea L. Harzstark · Principal investigator
  • The Permanente Medical Group-Roseville Radiation Oncology
    Roseville, California 95678, United States
    Recruiting
    • Site Public Contact · ContactKpoct@kp.org · 877-642-4691
    • Andrea L. Harzstark · Principal investigator
  • Kaiser Permanente Downtown Commons
    Sacramento, California 95814, United States
    Recruiting
    • Site Public Contact · Contactkpoct@kp.org · 877-642-4691
    • Andrea L. Harzstark · Principal investigator
  • Mercy Cancer Center - Sacramento
    Sacramento, California 95816, United States
    Recruiting
  • University of California Davis Comprehensive Cancer Center
    Sacramento, California 95817, United States
    Recruiting
    • Site Public Contact · Contact916-734-3089
    • Richard K. Valicenti · Principal investigator
  • Kaiser Permanente-South Sacramento
    Sacramento, California 95823, United States
    Recruiting
    • Site Public Contact · ContactKpoct@kp.org · 877-642-4691
    • Andrea L. Harzstark · Principal investigator
  • South Sacramento Cancer Center
    Sacramento, California 95823, United States
    Recruiting
    • Site Public Contact · ContactKpoct@kp.org · 877-642-4691
    • Andrea L. Harzstark · Principal investigator
  • Kaiser Permanente-San Francisco
    San Francisco, California 94115, United States
    Recruiting
    • Site Public Contact · ContactKpoct@kp.org · 877-642-4691
    • Andrea L. Harzstark · Principal investigator
  • Kaiser Permanente-Santa Teresa-San Jose
    San Jose, California 95119, United States
    Recruiting
    • Site Public Contact · ContactKpoct@kp.org · 877-642-4691
    • Andrea L. Harzstark · Principal investigator
  • Kaiser Permanente San Leandro
    San Leandro, California 94577, United States
    Recruiting
    • Site Public Contact · ContactKpoct@kp.org · 877-642-4691
    • Andrea L. Harzstark · Principal investigator
  • Pacific Central Coast Health Center-San Luis Obispo
    San Luis Obispo, California 93401, United States
    Recruiting
  • Kaiser San Rafael-Gallinas
    San Rafael, California 94903, United States
    Recruiting
    • Site Public Contact · ContactKpoct@kp.org · 877-642-4691
    • Andrea L. Harzstark · Principal investigator
  • Kaiser Permanente Medical Center - Santa Clara
    Santa Clara, California 95051, United States
    Recruiting
    • Site Public Contact · ContactKpoct@kp.org · 877-642-4691
    • Andrea L. Harzstark · Principal investigator
  • Kaiser Permanente-Santa Rosa
    Santa Rosa, California 95403, United States
    Recruiting
    • Site Public Contact · ContactKpoct@kp.org · 877-642-4691
    • Andrea L. Harzstark · Principal investigator
  • Kaiser Permanente Cancer Treatment Center
    South San Francisco, California 94080, United States
    Recruiting
    • Site Public Contact · ContactKpoct@kp.org · 877-642-4691
    • Andrea L. Harzstark · Principal investigator
  • Kaiser Permanente-South San Francisco
    South San Francisco, California 94080, United States
    Recruiting
    • Site Public Contact · ContactKpoct@kp.org · 877-642-4691
    • Andrea L. Harzstark · Principal investigator
  • Kaiser Permanente-Stockton
    Stockton, California 95210, United States
    Recruiting
    • Site Public Contact · ContactKpoct@kp.org · 877-642-4691
    • Andrea L. Harzstark · Principal investigator
  • Gene Upshaw Memorial Tahoe Forest Cancer Center
    Truckee, California 96161, United States
    Recruiting
    • Site Public Contact · Contact530-582-6450
    • Richard K. Valicenti · Principal investigator
  • Kaiser Permanente Medical Center-Vacaville
    Vacaville, California 95688, United States
    Recruiting
    • Site Public Contact · ContactKpoct@kp.org · 877-642-4691
    • Andrea L. Harzstark · Principal investigator
  • Kaiser Permanente-Vallejo
    Vallejo, California 94589, United States
    Recruiting
    • Site Public Contact · ContactKpoct@kp.org · 877-642-4691
    • Andrea L. Harzstark · Principal investigator
  • Kaiser Permanente-Walnut Creek
    Walnut Creek, California 94596, United States
    Recruiting
    • Site Public Contact · ContactKpoct@kp.org · 877-642-4691
    • Andrea L. Harzstark · Principal investigator
  • University of Colorado Hospital
    Aurora, Colorado 80045, United States
    Recruiting
    • Site Public Contact · Contact720-848-0650
    • Paul D. Maroni · Principal investigator
  • Rocky Mountain Cancer Centers-Boulder
    Boulder, Colorado 80304, United States
    Recruiting
  • UCHealth Memorial Hospital Central
    Colorado Springs, Colorado 80909, United States
    Recruiting
    • Site Public Contact · Contact719-365-2406
    • Paul D. Maroni · Principal investigator
  • Memorial Hospital North
    Colorado Springs, Colorado 80920, United States
    Recruiting
    • Site Public Contact · Contact719-364-6700
    • Paul D. Maroni · Principal investigator
  • Porter Adventist Hospital
    Denver, Colorado 80210, United States
    Recruiting
  • Shaw Cancer Center
    Edwards, Colorado 81632, United States
    Recruiting
    • Site Public Contact · Contact970-569-7429
    • Patricia H. Hardenbergh · Principal investigator
  • Poudre Valley Hospital
    Fort Collins, Colorado 80524, United States
    Recruiting
    • Site Public Contact · Contact970-297-6150
    • Paul D. Maroni · Principal investigator
  • North Colorado Medical Center
    Greeley, Colorado 80631, United States
    Recruiting
  • Littleton Adventist Hospital
    Littleton, Colorado 80122, United States
    Recruiting
  • McKee Medical Center
    Loveland, Colorado 80539, United States
    Recruiting
  • Parker Adventist Hospital
    Parker, Colorado 80138, United States
    Recruiting
  • Smilow Cancer Hospital Care Center - Guilford
    Guilford, Connecticut 06437, United States
    Recruiting
    • Site Public Contact · Contactcanceranswers@yale.edu · 203-785-5702
    • Preston C. Sprenkle · Principal investigator
  • Yale University
    New Haven, Connecticut 06520, United States
    Recruiting
    • Site Public Contact · Contactcanceranswers@yale.edu · 203-785-5702
    • Preston C. Sprenkle · Principal investigator
  • Stamford Hospital/Bennett Cancer Center
    Stamford, Connecticut 06904, United States
    Recruiting
    • Site Public Contact · Contact203-323-8944
    • Anthony P. Gulati · Principal investigator
  • Smilow Cancer Hospital Care Center-Trumbull
    Trumbull, Connecticut 06611, United States
    Recruiting
    • Site Public Contact · Contactcanceranswers@yale.edu · 203-785-5702
    • Preston C. Sprenkle · Principal investigator
  • Smilow Cancer Hospital Care Center - Waterford
    Waterford, Connecticut 06385, United States
    Recruiting
    • Site Public Contact · Contactcanceranswers@yale.edu · 203-785-5702
    • Preston C. Sprenkle · Principal investigator
  • Veterans Affairs Connecticut Healthcare System-West Haven Campus
    West Haven, Connecticut 06516, United States
    Recruiting
    • Site Public Contact · Contact203-937-3421
    • Preston C. Sprenkle · Principal investigator
  • Helen F Graham Cancer Center
    Newark, Delaware 19713, United States
    Recruiting
  • Christiana Care Health System-Christiana Hospital
    Newark, Delaware 19718, United States
    Recruiting
  • MedStar Georgetown University Hospital
    Washington D.C., District of Columbia 20007, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • MedStar Washington Hospital Center
    Washington D.C., District of Columbia 20010, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • George Washington University Medical Center
    Washington D.C., District of Columbia 20037, United States
    Recruiting
    • Site Public Contact · Contact202-741-2981
    • Michael J. Whalen · Principal investigator
  • Mount Sinai Comprehensive Cancer Center at Aventura
    Aventura, Florida 33180, United States
    Recruiting
    • Site Public Contact · Contactyenrique@msmc.com · 305-674-2625
    • Michael A. Schwartz · Principal investigator
  • UM Sylvester Comprehensive Cancer Center at Coral Gables
    Coral Gables, Florida 33146, United States
    Recruiting
    • Site Public Contact · Contact305-243-2647
    • Chad R. Ritch · Principal investigator
  • UM Sylvester Comprehensive Cancer Center at Deerfield Beach
    Deerfield Beach, Florida 33442, United States
    Recruiting
    • Site Public Contact · Contact305-243-2647
    • Chad R. Ritch · Principal investigator
  • Baptist MD Anderson Cancer Center
    Jacksonville, Florida 32207, United States
    Recruiting
    • Site Public Contact · Contact904-202-7468
    • Jonathan J. Melquist · Principal investigator
  • University of Miami Miller School of Medicine-Sylvester Cancer Center
    Miami, Florida 33136, United States
    Recruiting
    • Site Public Contact · Contact305-243-2647
    • Chad R. Ritch · Principal investigator
  • UM Sylvester Comprehensive Cancer Center at Kendall
    Miami, Florida 33176, United States
    Recruiting
    • Site Public Contact · Contact305-243-2647
    • Chad R. Ritch · Principal investigator
  • Mount Sinai Medical Center
    Miami Beach, Florida 33140, United States
    Recruiting
    • Site Public Contact · Contactyenrique@msmc.com · 305-674-2625
    • Michael A. Schwartz · Principal investigator
  • Orlando Health Cancer Institute
    Orlando, Florida 32806, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • UM Sylvester Comprehensive Cancer Center at Plantation
    Plantation, Florida 33324, United States
    Recruiting
    • Site Public Contact · Contact305-243-2647
    • Chad R. Ritch · Principal investigator
  • Grady Health System
    Atlanta, Georgia 30303, United States
    Recruiting
    • Site Public Contact · Contact404-489-9164
    • Shreyas Joshi · Principal investigator
  • Emory University Hospital Midtown
    Atlanta, Georgia 30308, United States
    Recruiting
    • Site Public Contact · Contact888-946-7447
    • Shreyas Joshi · Principal investigator
  • Emory University Hospital/Winship Cancer Institute
    Atlanta, Georgia 30322, United States
    Recruiting
    • Site Public Contact · Contact404-778-1868
    • Shreyas Joshi · Principal investigator
  • Emory Saint Joseph's Hospital
    Atlanta, Georgia 30342, United States
    Recruiting
    • Site Public Contact · Contact404-851-7115
    • Shreyas Joshi · Principal investigator
  • Augusta University Medical Center
    Augusta, Georgia 30912, United States
    Recruiting
    • Site Public Contact · Contactga_cares@augusta.edu · 706-721-2388
    • Sharad A. Ghamande · Principal investigator
  • Atlanta VA Medical Center
    Decatur, Georgia 30033, United States
    Recruiting
    • Site Public Contact · Contact404-321-6111
    • Wayne B. Harris · Principal investigator
  • Saint Alphonsus Cancer Care Center-Caldwell
    Caldwell, Idaho 83605, United States
    Recruiting
  • Saint Alphonsus Cancer Care Center-Nampa
    Nampa, Idaho 83687, United States
    Recruiting
    • Site Public Contact · Contactmccinfo@mtcancer.org · 406-969-6060
    • John M. Schallenkamp · Principal investigator
  • Kootenai Clinic Cancer Services - Post Falls
    Post Falls, Idaho 83854, United States
    Recruiting
    • Site Public Contact · Contactmccinfo@mtcancer.org · 406-969-6060
    • John M. Schallenkamp · Principal investigator
  • Rush - Copley Medical Center
    Aurora, Illinois 60504, United States
    Recruiting
  • Illinois CancerCare-Bloomington
    Bloomington, Illinois 61704, United States
    Recruiting
  • Illinois CancerCare-Canton
    Canton, Illinois 61520, United States
    Recruiting
  • Illinois CancerCare-Carthage
    Carthage, Illinois 62321, United States
    Recruiting
  • Northwestern University
    Chicago, Illinois 60611, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Rush University Medical Center
    Chicago, Illinois 60612, United States
    Recruiting
  • University of Illinois
    Chicago, Illinois 60612, United States
    Recruiting
    • Site Public Contact · Contact312-355-3046
    • Daniel Moreira · Principal investigator
  • University of Chicago Comprehensive Cancer Center
    Chicago, Illinois 60637, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Decatur Memorial Hospital
    Decatur, Illinois 62526, United States
    Recruiting
  • Crossroads Cancer Center
    Effingham, Illinois 62401, United States
    Recruiting

Showing the first 100 of 338 sites across 5 countries. Choose a country and city above to see the rest.

08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2018 (actual). Primary completion is estimated for Apr 2033, 174 months after the start.

Of 139 non-industry phase 3 interventional studies under Prostatic Neoplasms, half reached primary completion within 99 months of starting (the median), counting those still running; a quarter within 57 and three quarters within 144. This study's planned 174 months is above that.

Counting every sponsor, half of 266 studies reached it within 57 months; a quarter within 31 and three quarters within 100.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 8, 2026: primary completion Apr 2028 → Apr 2033 and completion Oct 2031 → Oct 2036.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2018
First posted
Sep 19, 2018
StartActual
Sep 24, 2018
Primary completionEst.
Apr 1, 2033was Apr 2028
CompletionEst.
Oct 1, 2036was Oct 2031
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Apr 1, 2028→Apr 1, 2033
Oct 8, 2026
Study completion
Oct 1, 2031→Oct 1, 2036
Oct 8, 2026
Show all 1 update
  1. Oct 8, 2026
    Primary completion Apr 1, 2028→Apr 1, 2033
    Study completion Oct 1, 2031→Oct 1, 2036
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT03678025
Responsible party
Sponsor
First posted
Sep 19, 2018
Start date
Sep 24, 2018
Primary completion
Apr 1, 2033 (estimated)
Completion
Oct 1, 2036 (estimated)
Last update
Oct 8, 2026

Study contacts

Dana Sparks, MAT
Contact
dsparks@swog.org
2106148808 ext. 1004
Brian Chapin
principal investigator · SWOG Cancer Research Network

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion